Track topics on Twitter Track topics that are important to you
(MedPage Today) -- Phase I trial in Crohn's disease patients shows full healing
TiGenix NV granted Takeda Pharmaceutical Co. Ltd. exclusive rights to develop and commercialize Cx601 in all territories outside of the US for perianal fistulas in patients with Crohn's disease.
Patients undergoing melanoma screening and surveillance should also undergo a screening of the perianal area for melanocytic nevi, which were associated with atypical nevi on other areas of the body, ...
"I was at death's door. I'd just lost my child who was stillborn and my husband abandoned me," recalls Hadiza Zakaria who suffered a fistula while pregnant—a condition seen as a curse in Niger.
The HSRIC has completed a horizon scanning review that identified new and emerging regenerative technologies for the treatment of gastrointestinal diseases including stomach, pancreas and colorectal c...
(HealthDay)—For patients with Crohn's disease, the risk of reoperation is increased for those with perianal lesions, according to a study published online Feb. 5 in the Journal of Gastroenterology a...
Cx601 appeared safe and effective for treatment of complex perianal fistulas in patients with Crohn’s disease refractory to antibiotics, immunosuppressants and/or anti-tumor necrosis factor therapy,...
Japanese company Takeda Pharmaceutical and Belgium-based TiGenix have entered into an ex-US licence, development and marketing agreement for Cx601 to treat complex perianal fistulas in patients with C...
Perianal fistula formation is a rare complication in children after rectal biopsy. Perianal fistula may become difficult to treat; therefore a lot of surgical options are present. One of these options...
Perianal fistulas are distressing for the patient and sometimes a challenge for the surgeon. Different methods for the treatment of perianal fistulas have a range of success rates and use of the cutti...